fluticasone furoate/umeclidinium/vilanterol vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 471 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs) During Run-in Period" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
Reported efficacy
Number of participants with Adverse Events (AEs) (Up to 3 months): Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). (not_applicable)
Result source: NCT06261957
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Salbutamol HFA-152a |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT04651777 | —Not reported |
| Trough FEV1, change | 0.1 vs 0.1vs FF/VINCT029246885 other results
| —Not reported |
| ACQ-5, change | —Trial running · NCT04651777 | —Not reported |
| OCS dose reduction | —Trial running · NCT04651777 | —Not reported |
Severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Salbutamol HFA-152a
- —Not reported
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
- Salbutamol HFA-152a
- —Not reported
ACQ-5, change
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Salbutamol HFA-152a
- —Not reported
OCS dose reduction
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Salbutamol HFA-152a
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Salbutamol HFA-152a: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol | Salbutamol HFA-152a |
|---|---|---|
| Dropout rate | 7.7%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | —800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0.7%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | —800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.4%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | 0%800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 100/31.25/25 mcga nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination | 800 ugb catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 5 more results
show 3 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Salbutamol HFA-152a's landscape